<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00104572</url>
  </required_header>
  <id_info>
    <org_study_id>999904338</org_study_id>
    <secondary_id>04-AG-N338</secondary_id>
    <nct_id>NCT00104572</nct_id>
  </id_info>
  <brief_title>Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.</brief_title>
  <official_title>The Effects of Aromatase Inhibition and Testosterone Replacement in Sex Steroids, Pituitary Hormones, Markers of Bone Turnover, Muscle Strength, and Cognition in Older Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Menâ‰¥65 years often produce lower levels of testosterone, meaning there is less
      testosterone circulating to the tissues of the body. This is associated with negative effects
      on muscle strength, bone density, sexual function, mood, and the ability to think to the best
      of one's ability. Testosterone replacement therapy often involves injections, patches, or
      gels that help to raise circulating testosterone levels, but these therapies often have side
      effects because they lead to imbalance of other hormones. Researchers have been studying the
      effectiveness of anastrozole, a drug that can lower estrogen levels while simultaneously
      increasing testosterone levels, as a treatment for the negative effects of decreased
      circulating testosterone levels that occur naturally with aging. Objectives: To evaluate
      whether anastrozole is as effective as testosterone gel in improving bone and muscle
      strength, hormone levels, and brain function in men over 65 years of age. Eligibility:
      Healthy men at least 65 years of age who have low levels of testosterone. Design: The study
      involves six study visits over a total of 12 months: screening, baseline, 6 weeks, 3 months,
      6 months, and 12 months. All participants will receive calcium and vitamin D supplements to
      take daily, and will be randomized to one of three groups:Testosterone gel and placebo
      tablet, Anastrozole tablet and placebo gel, Placebo tablet and gel. Participants will have
      the following tests at each specified visit:Screening: Blood tests and rectal ultrasound to
      evaluate the prostate;Baseline: Blood and urine tests; growth hormone levels, muscle
      strength, bone density, and balance evaluation; imaging studies; cognitive testing; and
      questionnaires on quality of life, sexual function, depression, and urinary symptoms;Six
      weeks: Blood tests and dose adjustment of the gel or tablet;Three months: Blood and urine
      tests; growth hormone, muscle strength, bone density, and balance evaluation; and
      questionnaires on quality of life, sexual function, depression, and urinary symptoms;Six
      months: Blood and urine tests; muscle strength, bone density, and balance evaluation;
      cognitive testing; and questionnaires on quality of life, sexual function, depression, and
      urinary symptoms;Twelve months: Blood and urine tests; rectal ultrasound; muscle strength,
      bone density, and balance evaluation; imaging studies; cognitive testing; and questionnaires
      on quality of life, sexual function, depression, and urinary symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 20% of men over the age of 70 have low testosterone levels. In some studies,
      testosterone replacement has resulted in improvement in bone mass, muscle strength, quality
      of life and memory function. In the body, testosterone is converted into estrogen. Hence, it
      is unclear whether these beneficial effects are due to testosterone or estrogen. Research has
      shown that inhibition of estrogen production in men results in an increase in testosterone
      levels.

      In this study, patients will be assigned to one of three groups: one group will receive
      testosterone gel and a placebo tablet, one group will receive a 1mg Anastrozole tablet and a
      placebo gel, and one group will receive a placebo tablet and placebo gel. Each group will
      receive a daily dose of calcium with vitamin D. The study requires 6 visits over a 12-month
      period for testing and evaluation. Two of the 6 visits will require an overnight stay in the
      hospital so that an intravenous (IV) line can be placed in the arm to allow samples to be
      drawn throughout the night. Testing will include a cardiac stress test, a glucose tolerance
      test, bone and muscle tests, evaluation of memory function, etc. For the safety of the
      prostate, we will perform a prostate ultrasound at the start and end of the study and we will
      monitor urinary symptoms, prostate specific antigen (PSA) levels and the prostate exam
      throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Testosterone Gel vs. Anastrozole on Bone Mineral Density</measure>
    <time_frame>1 year</time_frame>
    <description>bone mineral density lumbar spine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Testosterone Gel vs. Anastrozole on Cognitive Function</measure>
    <time_frame>1 year</time_frame>
    <description>MRI images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Testosterone Gel vs. Anastrozole on Pulsatile Growth Hormone Release</measure>
    <time_frame>1 year</time_frame>
    <description>Overnight Growth hormone measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Testosterone Gel vs. Anastrozole on Glucose Tolerance/Lipid Metabolism</measure>
    <time_frame>1 year</time_frame>
    <description>Oral glucose tolerance test (Glucose/Insulin), lipid profile, abdomen fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Testosterone Gel vs. Anastrozole on Prostate Volume/Prostate Specific Antigen Levels/Urinary Function</measure>
    <time_frame>1 year</time_frame>
    <description>rectal ultrasound and blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Testosterone Gel vs. Anastrozole on Gait/Balance Assessment</measure>
    <time_frame>1 year</time_frame>
    <description>gait measures</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Diabetes</condition>
  <condition>Sarcopenia</condition>
  <condition>Osteoporosis</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>17 participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>13 participants will receive a placebo tablet and placebo gel daily for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androgel (Testosterone Gel)</intervention_name>
    <description>1 mg tablet for 12 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole (Aromatase Inhibitor)</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Daily for 12 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel</intervention_name>
    <description>Daily for 12 months</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium Cardone 500mg with vitamin D 400 IU</intervention_name>
    <description>1 tablet three times a day</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Men age 65 years or older

               2. Serum testosterone level less than or equal to 350 ng/dl

               3. Subject is able to complete an informed consent

        EXCLUSION CRITERIA:

          1. History of Stroke

          2. History of Dementia

          3. History of Diabetes

          4. Blood pressure at rest of &gt; 155/90 mmHg. Elevated systolic or diastolic reading
             renders subject ineligible

          5. Chronic medical condition, i.e. congestive heart failure

          6. Arthritis, severe enough to prevent completion of the strength testing, history of
             joint replacement of knees or hip.

          7. Inability to walk 50 meters

          8. Known disease of the bone and/or taking medications to treat osteoporosis, i.e.

             Fosamax, Evista, Miacalcin

          9. History of Gastric surgery

         10. History of prostate cancer or any other cancers, including blood dyscrasias

         11. History of severe benign prostatic hyperplasia (causing urinary problems)

         12. History of heart attack or open-heart surgery within the past 6 months

         13. Use of steroids within the past 3 months, including prednisone and/or cortisone
             injections, and inhaled steroids. Topical steroid cream is acceptable.

         14. If you do not agree to refrain from taking the drugs Viagra, Cialis or Levitra for the
             duration of the study

         15. Use of anabolic steroids, i.e. testosterone, (or any analog of testosterone)
             Dehydroepiandrosterone or any growth promoters i.e. growth hormone itself or analogs
             of growth hormone

         16. Use of anti-androgen medications, i.e. Aldactone, Tagamet, Proscar, estrogens

         17. Use of Dilantin or Phenobarbital

         18. Alcohol intake &gt; 30 grams (drink more than 2 beers per day OR more than 1 glass of
             wine or cocktail daily)

         19. Currently smokes any tobacco product

         20. Having started a new medication during the past three months which may interfere with
             the outcome measures of the study

         21. Polycythemia

         22. Prostate specific antigen &gt; 4.0 ng/dl

         23. Hematocrit &lt; 36

         24. Liver function tests greater than 2 times upper normal limits or abnormal
             electrolytes, calcium or Parathyroid hormone , at the discretion of the investigator

         25. Mini Mental Status Exam score less than or equal to 24
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josephine M Egan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Aging (NIA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Aging, Clinical Research Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jeffcoate SL, Brooks RV, Lim NY, London DR, Prunty FT, Spathis GS. Androgen production in hypogonadal men. J Endocrinol. 1967 Apr;37(4):401-11.</citation>
    <PMID>4290227</PMID>
  </reference>
  <reference>
    <citation>Wheeler MJ. The determination of bio-available testosterone. Ann Clin Biochem. 1995 Jul;32 ( Pt 4):345-57. Review.</citation>
    <PMID>7486793</PMID>
  </reference>
  <reference>
    <citation>Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991 Nov;73(5):1016-25.</citation>
    <PMID>1719016</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2005</study_first_submitted>
  <study_first_submitted_qc>March 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2005</study_first_posted>
  <results_first_submitted>May 4, 2015</results_first_submitted>
  <results_first_submitted_qc>February 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2016</results_first_posted>
  <last_update_submitted>March 11, 2016</last_update_submitted>
  <last_update_submitted_qc>March 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Estrogen</keyword>
  <keyword>Glucose Tolerance</keyword>
  <keyword>Bone Density</keyword>
  <keyword>Quality-of-Life</keyword>
  <keyword>Sarcopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study randomized 44 subjects, however 9 of them stop the study before having the second visit completed, so we started the analysis with 35 subjects. The participant flow module has 35 subjects, because these subjects have a baseline and 3 months endpoints.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Transdermal Testosterone</title>
          <description>13 participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months
Androgel (Testosterone Gel): 1 mg tablet for 12 months
Placebo tablet: Daily for 12 months
Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day</description>
        </group>
        <group group_id="P2">
          <title>Aromatase Inhibitor</title>
          <description>13 participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months
Anastrozole (Aromatase Inhibitor)
Placebo gel: Daily for 12 months
Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>9 participants will receive a placebo tablet and placebo gel daily for 12 months
Placebo tablet: Daily for 12 months
Placebo gel: Daily for 12 months
Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13">These are the analysed subjects</participants>
                <participants group_id="P2" count="13">These are the analysed subjects</participants>
                <participants group_id="P3" count="9">(N=11) in placebo, physician removed 2 men due to total testosterone&gt;450 ng/DL, N=9 analysed.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transdermal Testosterone</title>
          <description>participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months
Androgel (Testosterone Gel): 1 mg tablet for 12 months
Placebo tablet: Daily for 12 months
Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day</description>
        </group>
        <group group_id="B2">
          <title>Aromatase Inhibitor</title>
          <description>participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months
Anastrozole (Aromatase Inhibitor)
Placebo gel: Daily for 12 months
Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>participants will receive a placebo tablet and placebo gel daily for 12 months
Placebo tablet: Daily for 12 months
Placebo gel: Daily for 12 months
Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="5.1"/>
                    <measurement group_id="B2" value="70" spread="3.0"/>
                    <measurement group_id="B3" value="72" spread="3.4"/>
                    <measurement group_id="B4" value="71" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137.8" spread="9.4"/>
                    <measurement group_id="B2" value="134.5" spread="14.5"/>
                    <measurement group_id="B3" value="133.7" spread="11.2"/>
                    <measurement group_id="B4" value="135.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.3" spread="5.3"/>
                    <measurement group_id="B2" value="72.4" spread="9.4"/>
                    <measurement group_id="B3" value="73.1" spread="10.4"/>
                    <measurement group_id="B4" value="72.9" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.1" spread="4.0"/>
                    <measurement group_id="B2" value="27.8" spread="4.1"/>
                    <measurement group_id="B3" value="27.6" spread="3.5"/>
                    <measurement group_id="B4" value="28.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Testosterone</title>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300.1" spread="81.9"/>
                    <measurement group_id="B2" value="271.6" spread="85.6"/>
                    <measurement group_id="B3" value="303.8" spread="94.7"/>
                    <measurement group_id="B4" value="291.8" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bioavailable Testosterone</title>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114.4" spread="37.2"/>
                    <measurement group_id="B2" value="114.8" spread="36.3"/>
                    <measurement group_id="B3" value="91.2" spread="31.7"/>
                    <measurement group_id="B4" value="106.8" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estradiol</title>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" spread="0.7"/>
                    <measurement group_id="B2" value="1.5" spread="0.6"/>
                    <measurement group_id="B3" value="1.6" spread="0.5"/>
                    <measurement group_id="B4" value="1.700" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex hormone-binding globulin</title>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.4" spread="22.2"/>
                    <measurement group_id="B2" value="39.9" spread="19.4"/>
                    <measurement group_id="B3" value="58.6" spread="21.3"/>
                    <measurement group_id="B4" value="47.30" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>luteinizing hormone</title>
          <units>mlU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.4" spread="8.2"/>
                    <measurement group_id="B2" value="6.4" spread="2.7"/>
                    <measurement group_id="B3" value="12.2" spread="10.1"/>
                    <measurement group_id="B4" value="10.00" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>follicle-stimulating hormone</title>
          <units>mlU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" spread="6.4"/>
                    <measurement group_id="B2" value="6.5" spread="5.3"/>
                    <measurement group_id="B3" value="8.2" spread="10.9"/>
                    <measurement group_id="B4" value="7.567" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone mineral density</title>
          <units>g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.4" spread="0.2"/>
                    <measurement group_id="B2" value="1.3" spread="0.2"/>
                    <measurement group_id="B3" value="1.2" spread="0.1"/>
                    <measurement group_id="B4" value="1.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>lean body mass</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.0" spread="12"/>
                    <measurement group_id="B2" value="54.7" spread="11.0"/>
                    <measurement group_id="B3" value="56.0" spread="7.2"/>
                    <measurement group_id="B4" value="55.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fat mass</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.6" spread="10.4"/>
                    <measurement group_id="B2" value="26.9" spread="9.6"/>
                    <measurement group_id="B3" value="28.5" spread="7.6"/>
                    <measurement group_id="B4" value="29.0" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>hand grip</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="6.9"/>
                    <measurement group_id="B2" value="39.2" spread="9.9"/>
                    <measurement group_id="B3" value="39.3" spread="7.2"/>
                    <measurement group_id="B4" value="39.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>knee strength</title>
          <units>Nm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133.8" spread="44.3"/>
                    <measurement group_id="B2" value="138.7" spread="48.6"/>
                    <measurement group_id="B3" value="155.4" spread="41.9"/>
                    <measurement group_id="B4" value="142.6" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Testosterone Gel vs. Anastrozole on Bone Mineral Density</title>
        <description>bone mineral density lumbar spine</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transdermal Testosterone</title>
            <description>participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months
Androgel (Testosterone Gel): 1 mg tablet for 12 months
Placebo tablet: Daily for 12 months
Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day</description>
          </group>
          <group group_id="O2">
            <title>Aromatase Inhibitor</title>
            <description>participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months
Anastrozole (Aromatase Inhibitor)
Placebo gel: Daily for 12 months
Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>participants will receive a placebo tablet and placebo gel daily for 12 months
Placebo tablet: Daily for 12 months
Placebo gel: Daily for 12 months
Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Testosterone Gel vs. Anastrozole on Bone Mineral Density</title>
          <description>bone mineral density lumbar spine</description>
          <units>g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.042" spread="0.008"/>
                    <measurement group_id="O2" value="0.008" spread="0.012"/>
                    <measurement group_id="O3" value="0.047" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Testosterone Gel vs. Anastrozole on Cognitive Function</title>
        <description>MRI images</description>
        <time_frame>1 year</time_frame>
        <posting_date>12/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Testosterone Gel vs. Anastrozole on Pulsatile Growth Hormone Release</title>
        <description>Overnight Growth hormone measures</description>
        <time_frame>1 year</time_frame>
        <posting_date>12/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Testosterone Gel vs. Anastrozole on Glucose Tolerance/Lipid Metabolism</title>
        <description>Oral glucose tolerance test (Glucose/Insulin), lipid profile, abdomen fat</description>
        <time_frame>1 year</time_frame>
        <posting_date>07/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Testosterone Gel vs. Anastrozole on Prostate Volume/Prostate Specific Antigen Levels/Urinary Function</title>
        <description>rectal ultrasound and blood test</description>
        <time_frame>1 year</time_frame>
        <posting_date>07/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Testosterone Gel vs. Anastrozole on Gait/Balance Assessment</title>
        <description>gait measures</description>
        <time_frame>1 year</time_frame>
        <posting_date>07/2016</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The study randomized 44 subjects, however 9 of them stop the study before having the second visit completed, so we started the analysis with 35 subjects. The participant flow module has 35 subjects, because these subjects have a baseline and 3 months endpoints.</desc>
      <group_list>
        <group group_id="E1">
          <title>Transdermal Testosterone</title>
          <description>participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months
Androgel (Testosterone Gel): 1 mg tablet for 12 months
Placebo tablet: Daily for 12 months
Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day</description>
        </group>
        <group group_id="E2">
          <title>Aromatase Inhibitor</title>
          <description>participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months
Anastrozole (Aromatase Inhibitor)
Placebo gel: Daily for 12 months
Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>participants will receive a placebo tablet and placebo gel daily for 12 months
Placebo tablet: Daily for 12 months
Placebo gel: Daily for 12 months
Calcium Cardone 500mg with vitamin D 400 IU: 1 tablet three times a day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>subdural hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>mildly elevated HCT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>increased heart rate palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness/diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle ache</sub_title>
                <description>in aromatase group</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>muscle ache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>bladder mass</sub_title>
                <description>bladder mass on transrectal exam</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>elevated PSA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>elevated PSA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>blood in semen</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea on exertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>stent placement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Josephine M. Egan,MD, clinical director NIA</name_or_title>
      <organization>NIA</organization>
      <phone>410-558-8414</phone>
      <email>eganj@grc.nia.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

